Maisel Urges Caution In Adoption Of Atritech’s Watchman Anti-Stroke Device
This article was originally published in The Gray Sheet
Executive Summary
If approved by FDA, Atritech's Watchman left-atrial appendage occluder should not be routinely implanted in atrial fibrillation patients to prevent strokes until more is known about the long-term safety and efficacy of the device, according to cardiologist and device safety expert William Maisel
You may also be interested in...
Left Atrial Appendage Closure Studies: FDA Offers Tips
The clinical path toward FDA approval of a left atrial appendage closure system for preventing stroke in atrial fibrillation patients has not been simple so far, informing the agency’s current expectations.
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Boston Scientific will acquire the Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation through its Jan. 19 purchase of Atritech for up to $375 million.
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Boston Scientific will acquire the Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation through its Jan. 19 purchase of Atritech for up to $375 million.